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Objective:One of the contributingmechanisms in acutemyocardial infarction (AMI) is plasmahypercoagulability.
Recently, it was suggested that factor XI activation might play a role in atherothrombosis. To quantify factor XIa
plasma levels, we developed a new thrombin generation based assay and hypothesized that in AMI patients
factor XIa levels are increased during the acute thrombotic event.
Methods: A prospective cohort study was performed including 56 patients with ﬁrst AMI. Blood was collected
upon admission and after 6 months. Reference blood samples were obtained from 30 apparently healthy control
subjects. Plasma samples were diluted (1:5) in factor XI deﬁcient plasma and factor XIa plasma levels were
established using a reference curve (0-12.5 pM factor XIa) and an inhibitory anti-factor XIa antibody. The
established FXIa concentrations were related to the 1-year outcome.
Results: Factor XIa plasma concentrations were signiﬁcantly increased in AMI patients on admission compared to
6 months after the event (3.7 pM [2.7-5.5] vs. 2.8 [1.9-4.3], median ± IQR; P= 0.001) and compared to healthy
controls (3.7 pM [2.7-5.5] vs. 2.7 [1.6-4.2], median ± IQR; P= 0.004). However, a high factor FXIa level at base-
line was not signiﬁcantly associated with a recurrent cardiovascular event (OR 1.26, 95%CI 0.33-4.7).
Conclusions: This study presents the ﬁrst application of a new thrombin generation based factor XIa assay, show-
ing signiﬁcantly increased factor XIa levels in AMI patients on admission compared to 6 months after the event
and compared to healthy controls. The factor XIa concentration was not associated with the risk of recurrence.© 2014 Elsevier Ltd. All rights reserved.Introduction
The central role of thrombosis in the pathogenesis of cardiovascular
disease has led to an increasing interest in the relationship between
speciﬁc coagulation proteases and cardiovascular disease. Several stud-
ies have demonstrated that coagulation proteins like ﬁbrinogen, factors
VII and VIII, as well as markers of activated coagulation, including
thrombin-antithrombin complexes and D-dimer, are associated with
cardiovascular risk [1–3]. More recently, it has been suggested that the
activation of factor XI may also be involved in atherothrombotic events
[4–6].
The knownphysiological plasma activators of factor XI are factor XIIa
[7] and thrombin [8,9]. The activation of factor XI by thrombin serves asThrombosis and Haemostasis,
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l (R. Loeffen).a feedbackmechanism to amplify thrombin generation following its ini-
tial formation by the tissue factor (TF) - factor VII pathway [8]. Further-
more, through amplifying thrombin generation, factor XIa indirectly
protects the clot from lysis through the activation of thrombin-
activatable ﬁbrinolysis inhibitor by thrombin [10,11]. Thus, factor XIa
acts both as a direct procoagulant and indirect anti-ﬁbrinolytic factor.
Results from animal models and clinical studies have revealed that
factor XI is involved in thrombotic diseases. Factor XI-null mice demon-
strated protection against thrombosis without impairing hemostasis
[12,13], and in humans, factor XI deﬁciency (hemophilia C) showedpro-
tective effects against venous thrombosis and ischemic stroke [14,15].
Furthermore, high levels of factor XI were associated with thrombotic
diseases, both venous [16,17] and arterial thrombosis [18,19].
Regarding the activity of factor XI,Minnema et al. demonstrated that
in patients with MI factor XI activity was increased, as suggested by the
presence of factor XIa-C1 inhibitor complexes in 24% of patients with
acute myocardial infarction (AMI) and 8% of patients with unstable
angina pectoris [5]. Furthermore, quantiﬁable plasma levels of factor
XIa were detected in most patients with acute coronary syndrome and
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XIa levels were assessed through determination of the prolongation of
the clotting time upon addition of an inhibitory antibody for factor XIa.
This may result in a partial detection of circulating factor XIa or an over-
estimation due to an antibody induced shift from inhibitor-complexed
factor XIa towards the free enzyme form. Therefore, and in order to fur-
ther study the role of factor XIa in cardiovascular diseases we developed
a new thrombin generation based assay enabling the direct quantiﬁca-
tion of plasma factor XIa levels. In thepresent studywe report the devel-
opment of this modiﬁed Calibrated Automated Thrombogram (CAT)
assay and the use of this novel laboratory tool to quantify factor XIa
levels in plasma from AMI patients and healthy volunteers.
Methods
Factor XIa CAT assay
Assay
Plasma levels of factor XIa were assessed using the CAT method
(Thrombinoscope BV, Maastricht, The Netherlands), under adjusted test-
ing conditions. The CAT method employs a low afﬁnity ﬂuorogenic sub-
strate for thrombin (Z-Gly-Gly-Arg-AMC) to continuously monitor
thrombin activity in clotting plasma. In the factor XIa CAT assay all throm-
bin generation measurements were conducted in the absence of tissue
factor and activation was only by addition of (ﬁnal concentration) 4 μM
phospholipids vesicles (PL; Thrombinoscope BV) at 20:20:60 mol% PS:
PE:PC. To inhibit the extrinsic coagulation pathway, active site inhibited
factor VIIa (ASIS, Novo Nordisk, Bagsvaerd, Denmark) was added at a
ﬁnal concentration of 30 nM, as described previously [20]. All plasma
samples were diluted at a 1:5 ratio in immunodepleted factor XI deﬁcient
plasma (Haematologic Technologies Inc., Essex Junction, VT, USA). Factor
XIa plasma levels were calculated from a reference curve developed with
eight sequential dilutions of puriﬁed human factor XIa (0-12.5 pM;
Haematologic Technologies Inc.) in a plasmamixture (1:5 ratio) of pooled
corn trypsin inhibitor (CTI) plasma from 30 healthy volunteers and factor
XI deﬁcient plasma. Patients’ citrated plasma samples were diluted in the
samemanner in factor XI deﬁcient plasma (1:5 ratio),with addition of CTI
at a ﬁnal concentration of 25 μg/mL, to inhibit factor XIIa. Measurements
were conducted in 80 μL platelet-poor plasma mixture in a total volume
of 120 μL (20 μL ﬂuorogenic substrate, calcium chloride (FluCa) and
20 μL trigger reagent). All patients’ plasma samples were analyzed in du-
plicate. In order to correct for inner-ﬁlter effects and substrate consump-
tion, each thrombin generation measurement was calibrated against the
ﬂuorescence curve obtained in a sample from the same plasma (80 μL),
added with a ﬁxed amount of thrombin-α2-macroglobulin complex
(20 μL Thrombin Calibrator, Thrombinoscope BV) and 20 μL FluCa. Mea-
surements were performed after 10 minutes (min) of preheating at
37 °C in the ﬂuorometer. Fluorescence was read in a Fluoroskan Ascent
reader (Thermo Labsystems OY, Helsinki, Finland) equipped with a 390/
460 ﬁlter set and thrombin generation curves were calculated with the
Thrombinoscope software (Thrombinoscope BV).
Validation
The thrombin generation based factor XIa CAT assay was validated
through the Clinical and Laboratory Standards Institute (CLSI) EP5 proto-
col [21]. To determine the within-run and between-run variability of the
method, factor XIa measurements were performed for 10 days with two
runs a day. In every run the factor XIa reference curve and two internal
control samples (1 and 4 pM factor XIa) were analyzed in duplicate.
Anti-factor XIa antibody
All patients’ plasma samples were measured in the absence and
presence of an inhibitory monoclonal antibody directed against factor
XIa, to establish that the endogenous factor XIa plasma level was the
only determinant of the thrombin generation curve. For the develop-
ment of a potent anti-factor XIa antibody we used heavy chainantibodies obtained from the serum of Camelideae that recognize the
antigen by a single variable-domain heavy-chain (VHHor NanobodyTM)
[22]. VHHs were raised by immunizing llamaswith puriﬁed human fac-
tor XIa using a standard immunization protocol, followed by phage dis-
play to select for phages that bind to factor XIa [23]. Soluble VHHs were
produced by E. Coli and puriﬁed as described previously [24]. Afﬁnity
constants for the binding between the selected VHH and factor XIa
were determined by surface plasmon resonance analysis using a Biacore
T200 analytical system (GE healthcare, Uppsala, Sweden) equipped
with a CM-5 sensor chip. The VHH was covalently coupled up to 250
resonance units (5 μg/ml in 10 mM of acetate buffer pH 4.0) and pu-
riﬁed factor XIa was injected at concentrations between 4.5 and 300
nM (in 25 mM Hepes buffer with 0.05% Tween-20 pH 7.4) at a ﬂow
rate of 40 μl/min. After each cycle regeneration of the chip was per-
formed by 10 μl of glycine-HCl (10 mM pH 2.0). Calculated Kd values
were determined by steady-state evaluation of global curve ﬁts using
BIAevaluation software (version 1.1.1, Biacore company AB, Sweden).
The antibody’s inhibitory effect was established using the CAT assay, by
addition of an enzyme concentration of ≥1% of the total zymogen
concentration (enzyme concentration that mimics 1% activation) in nor-
mal plasma of puriﬁed factor IXa (1000 pM; Haematologic Technologies
Inc.), factor Xa (1500 pM; Haematologic Technologies Inc.) or factor XIa
(400 pM) to a plasma mixture of pooled CTI plasma and factor XI
deﬁcient plasma (1:5 ratio). In parallel, the anti-factor XIa antibody at a
ﬁnal concentration of 1000 nM was added to the same plasma sample,
after which thrombin generation was measured. Comparable factor XIa
inhibition experiments were performed with patients’ plasma samples
using a ﬁnal concentration of 100 nM inhibitory anti-factor XIa antibody.
Stability of factor XIa
Stability experiments were performed to determine the stability of
puriﬁed factor XIa inwhole blood. Citratedwhole blood samples collect-
ed from three healthy volunteers were incubated with 20 or 40 pM
factor XIa for 15, 30, 40, 60 and 120 min at room temperature, followed
by two-step centrifugation (15 min at 2000 x g, followed by 10 min at
11.000 x g). One samplewas used as a reference sample and centrifuged
immediately. All plasma aliquots were snap-frozen in liquid nitrogen
and stored at -80 °C until analysis.
Prospective cohort study in AMI patients
Study design & population
This study has been described in detail elsewhere [25]. Eligible
patients presented between January 2004 and April 2006 with a ﬁrst
AMI at the Cardiac Care Unit of the Maastricht University Medical
Center. AMI was deﬁned as chest pain for more than 30 min but not ex-
ceeding 24 hours, ST-segment elevation N1mmon electrocardiography
and biochemical evidence of myocardial necrosis. Subjects with a histo-
ry of MI or stroke and present use of oral anticoagulants were excluded.
Blood samples were collected upon admission, before administration of
low-molecular-weight heparin (LMWH) or any other intervention, and
subsequently after 6 months. Clinical outcome was recorded 3, 6 and
12 months after inclusion and comprised the combined endpoint of car-
diovascular death, recurrentMI, a second coronary intervention (percu-
taneous coronary intervention or coronary artery bypass grafting), and
ischaemic stroke. Reference blood samples were obtained from 30
age- and sex-matched, apparently healthy control subjects. All partici-
pants provided written informed consent and the study was conducted
according to the principles of the Declaration of Helsinki and the laws
and regulations applicable in the Netherlands. The local institutional
review board approved the conduct of this study.
Blood collection and preparation
Venous blood from both patients and control subjects was collected
from the antecubital vein using 21-gauge needles and 3.2% (w/v)
citrated tubes (Becton Dickinson, Plymouth, UK). Samples were
1330 R. Loeffen et al. / Thrombosis Research 134 (2014) 1328–1334centrifuged within 1 hour after receiving the whole blood tubes.
Platelet-poor plasma was obtained by two separate centrifugation
steps of 15 min at 2000 x g, followed by 10 min at 11.000 x g. Directly
after preparation through centrifugation aliquots were snap-frozen in
liquid nitrogen and stored at -80 °C until analysis. Anti-Xa activity was
determined in all baseline samples using the Coamatic Heparin test (In-
strumentation Laboratory, Breda, The Netherlands) to rule out any acci-
dental administration of LMWH before blood sampling. Only samples
with undetectable anti-Xa levels (≤0.05 U mL-1) were considered to
be free of LMWH and were included in the study. For the factor XIa ref-
erence curve, CTI plasma was obtained from 30 healthy volunteers
(Maastricht University Medical Center, The Netherlands) using SCAT
4.5 mL, 50 μg/mL CTI/3.2 %(w/v) citrate tubes (Haematologic Technolo-
gies Inc.), followed by two-step centrifugation (15 min at 2000 x g,
followed by 10min at 11.000 x g) and pooling of platelet-poor plasmas.
Coagulation markers
Thrombin generation in platelet-poor plasma was measured by
means of the CAT method, according to our previously described stan-
dardized protocol [26]. Measurements were performed at a ﬁnal con-
centration of 1 pM TF in the presence of 4 μM PL. Three parameters
were derived from the thrombin generation curves: lag time, endoge-
nous thrombin potential (ETP, area under the curve) and peak height.
The time-independent parameters ETP and peak height were normal-
ized based on the results of normal pooled plasma obtained from
healthy volunteers, which was used as a reference [27]. The normalized
ETP and peak height are expressed as % of normal pooled plasma. Plas-
ma concentrations of factor XIc, ﬁbrinogen and D-dimer were
established using a Sysmex® CA-7000 System Automated Coagulation
Analyzer with reagents obtained from Dade Behring Inc. (Liederbach,
Germany). D-dimer measurements were performed using the D-
dimer Plus test according to themanufacturer’s instructions (Dade Beh-
ring Inc.). Fibrinogen levels were measured using the Clauss method
and factor XIc levels were assessed using a one-stage aPTT based
clotting assay. The levels of factor XIa in complex with C1-esterase
inhibitor andα1-antitrypsin were established using enzyme-linked im-
munosorbent assays (ELISAs), as previously described [28,29].
Statistical analysis
Statistical analysis was performed with PRISM for Mac, version 6.00
(GraphPad Software, San Diego, CA, USA), and SPSS version 21.0 (SPSS
inc. Chicago, IL, USA). According to the distribution of variables
(D’agostino & Pearson omnibus normality test), data are expressed as
median ± interquartile range (IQR) or mean with range in the case of
age. Categorical variables are expressed as number with percentage
(%). Differences between groups were analyzed using a chi-square test
(χ2), Mann-Whithey U test orWilcoxonmatched pairs test as appropri-
ate. Nonlinear regression analysis of the reference curve peak height
values, using a hyperbola curve ﬁt, was used to establish the factor XIa
concentrations of the plasma samples. The associations between dichot-
omized levels of factor XIa and outcomewas assessed using Pearson chi-
square test. Potential confounders (baseline characteristicswith P-value
≤0.1 in chi-square or Mann-Whitney U test) were included in the
model. Results are reported as odds ratios (ORs) with 95% conﬁdence
intervals (95% CI) and corresponding P-values. A two-tailed probability
value of P b 0.05 was considered statistically signiﬁcant.
Results
Development and validation of the factor XIa CAT assay
For the factor XIa CAT assay, all plasma sampleswere diluted at a 1:5
ratio in factor XI deﬁcient plasma to obtain factor XI concentra-
tions≤ 20% and to equalize plasma concentrations of all other coagula-
tion proteins between the different plasma samples. To determine thefactor XIa plasma concentration in an individual plasma sample, a factor
XIa reference curve was constructed by the addition of eight sequential
dilutions of puriﬁed factor XIa (0-12.5 pM) in a plasma mixture of
pooled CTI plasma and factor XI deﬁcient plasma (Fig. 1A). The peak
height was used as the main thrombin generation parameter to obtain
the factor XIa reference curve. By plotting the peak height values against
the added factor XIa concentrations using a hyperbola curve ﬁt, the
factor XIa reference curve was obtained (Fig. 1B). Validation of the
assay resulted in coefﬁcients of variation (CV) of the within-run and
between-run variation of 11.9% and 11.5% for the 4 pM factor XIa control
sample, and 16.2% and 15.8% for the 1 pM factor XIa control sample,
respectively.
Application of an inhibitory anti-factor XIa antibody
To conﬁrm that the established thrombin generation curves were
determined by endogenous factor XIa plasma levels, a set of control
experiments was performed using a single variable-domain heavy-
chain antibody directed against factor XIa. As depicted in Fig. 1C, the
binding afﬁnity of the anti-factor XIa antibody determined by surface
plasmon resonance analysis demonstrated a high binding afﬁnity of fac-
tor XIa for the antibody (Kd 5.7 nM). Furthermore, thrombin generation
performed in a mixture of pooled CTI plasma and factor XI deﬁcient
plasma triggered with factor XIa was abolished upon addition of the
anti-factor XIa antibody (Fig. 1F). Since circulating factor IXa or Xa
might induce thrombin generation in the setup of plasma diluted at a
1:5 ratio in factor XI deﬁcient plasma,we investigated the effect of addi-
tion of these coagulation enzymes. Plasma samples were supplemented
with 1000 pM factor IXa or 1500 pM factor Xa (enzyme concentration
that mimics 1% activation), diluted 1:5 in factor XI deﬁcient plasma
and thrombin generation was recorded. Both factor IXa and Xa induced
thrombin generationwith a peak height of 350 nM and 100 nM, respec-
tively (Fig. 1D, E). In contrast to themeasurements triggeredwith factor
XIa, addition of the anti-factor XIa antibody did not result in inhibition
of the thrombin generation curves triggered with factor IXa or Xa
(Fig. 1D, E). Further experiments, which employed the measurement
of patients’ plasma samples with addition of CTI, in the presence and
absence of the anti-factor XIa antibody (ﬁnal concentration 100 nM),
showed that thrombin generation was inhibited in all patients’ samples
upon addition of the inhibitory anti-factor XIa antibody. This conﬁrms
that, within the present patient cohort, the only trigger for thrombin
generation in the factor XIa CAT assay is the endogenous activated factor
XI.
Stability of factor XIa
In order to establish the stability of puriﬁed factor XIa added to
whole blood, stability experiments were performed with 20 and 40
pM factor XIa added to the whole blood of three healthy donors with
a subsequent incubation period of 0, 15, 30, 45, 60 and 120 min at
room temperature. Whereas factor XIa was stable up to 30 minutes,
levels dropped by 11% (8-15%) % at 45 min, 20% (14-27%) at 60 min
and by 38% (33-40%) at 120 min (median ± IQR). Therefore, plasma
aliquots should be prepared within the shortest time frame to avoid
degradation or inhibition of factor XIa. Unfortunately, these data cannot
be extrapolated to stability of endogenous factor XIa.
Patients and control population
In total, 135 patients were enrolled between January 2004 and April
2006. From the original study sample, 56 complete sets of plasma sam-
ples from the two main time points (baseline and 6 months follow-up)
were available for factor XIa measurement. In total, 16 patients were
excluded because anti-Xa levels were N0.05 U/mL. The baseline charac-
teristics and corresponding factor XIa levels of the 56 AMI patients are
presented in Table 1. The mean age on admission was 60 (range 34-
Fig. 1. Factor XIa reference curve and the application of an inhibitory anti-factor XIa antibody. Thrombin generation analysis (0 pMTF, 4 μMPL) performed in a plasmamixture of 20%
pooled CTI plasma of healthy volunteers and 80% factor XI deﬁcient plasma with addition of eight sequential dilutions of puriﬁed factor XIa (panel A), resulting in a factor XIa reference
curve by plotting of the peak height values against the added factor XIa concentrations using a hyperbola curve ﬁt (B). Binding afﬁnity of anti-factor XIa antibody determined by surface
plasmon resonance (C). Thrombin generation analysis (0 pM TF) measured in the absence and presence of an anti-factor XIa antibody triggered with puriﬁed factor IXa (D), Xa (E) or
XIa (F).
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population, included in 2012, consisted of 30 subjects, 70% (n = 21)
male and themean agewas 60 (range 40-72) years. The factor XIa levels
on admission did not differ between patients stratiﬁed for smoking, the
presence of hypercholesterolemia and did not correlate with age. We
cannot conclude that factor XIa levels on admission did not differ be-
tween diabetes and non-diabetes patients, since the number of diabetes
subjects was too small (n = 4). However, there was a signiﬁcant
increase in factor XIa levels in patients with hypertension at baseline
(5.1 pM [3.6-8.2] vs. 3.5 [2.3-8.2], median ± IQR; P= 0.036). Further-
more, factor XIa levels were higher in male patients compared to
females, however, this difference was not signiﬁcant (4.1 pM [2.9-6.3]
vs. 3.1 [2.0-5.0], median ± IQR; P= 0.078).Table 1
Baseline characteristics with distribution of factor XIa levels of AMI patients (N = 56).
Total group Factor XIa [pM] P-value
Age, yrs (range) 60 (34-86)
≥60 4.4 (2.7-7.4) 0.226
b60 3.4 (2.6-4.7)
Sex,m (%) 40 (71)
male 4.1 (2.9-6.3) 0.078
female 3.1 (2.0-5.0)
Hypertension, n (%) 11 (20)
yes 5.1 (3.6-8.2) 0.036
no 3.5 (2.3-5.2)
Diabetes type II, n (%) 4 (7)
yes 4.6 (3.8-5.4) 0.399
no 3.5 (2.6-5.8)
Hypercholesterolemia, n (%) 14 (25)
yes 4.1 (2.9-7.0) 0.797
no 3.7 (2.5-5.3)
Smoking, n (%) 30 (54)
yes 3.5 (2.6-4.8) 0.209
no 4.8 (2.7-8.4)Factor XIa plasma levels in AMI
Fig. 2A shows the factor XIa plasma levels in AMI patients on admis-
sion and at 6 months follow-up, and in the apparently healthy control
population. The factor XIa plasma concentrations were signiﬁcantly in-
creased in AMI patients during the acute event compared to the steady
state situation 6 months after the AMI (3.7 pM [2.7-5.5] vs. 2.8 [1.9-4.3],
median ± IQR; P = 0.001). Compared to the acute phase of MI, the
median level of factor XIa declined by 24% at 6 months follow-up.
Also, factor XIa plasma levels at baseline were signiﬁcantly higher com-
pared to the factor XIa levels in apparently healthy control subjects (3.7
pM [2.7-5.5] vs. 2.7 [1.6-4.2], median ± IQR; P= 0.004). No signiﬁcant
difference in factor XIa concentration was demonstrated between AMI
patients at 6 months follow-up and apparently healthy controls. Addi-
tion of the anti-factor XIa antibody to the patients and control samples
resulted in complete inhibition of thrombin generation (Fig. 2B,C).
Results of the measurements of factor XIa and other coagulation
markers in AMI patients on admission and at 6 months follow-up are
presented in Table 2. Comparable to the factor XIa plasma levels, throm-
bin generation was enhanced at baseline, as demonstrated by a signiﬁ-
cant shortening of the lag time and a signiﬁcant increase in normalized
ETP and peak height. The median D-dimer and ﬁbrinogen levels were
within the normal reference ranges of these measurements and did
not signiﬁcantly change after 6 months follow-up. Regarding the levels
of factor XIa inhibitor complexes, we found that the level of factor XIa-
C1 inhibitor was signiﬁcantly higher during the acute event compared
to 6 months after the AMI. However, this effect was not observed for
factor XIa-α1-antitrypsin. The median Factor XIc concentration in AMI
patients on admission was 123 U/dL (IQR: 110-132), which was within
the normal reference range (70-150 U/dL). In the healthy control group
the factor XIc level was 93 (IQR: 82-100), also within the normal refer-
ence range. However, compared to the factor XIc concentration in
healthy controls, the level was signiﬁcantly higher in AMI patients
(P b 0.0001) (data not shown).
Fig. 2. Factor XIa plasma levels in patients and healthy controls. Plasma levels of factor XIa of patients after an acutemyocardial infarction (AMI) (N= 56)measured on admission and
after 6 months follow-up, and in apparently healthy control subjects (N= 30) (A). Individual patient’s plasma samples measured in the absence and presence of an inhibitory anti-factor
XIa antibody (B,C). Differences between the groups were determined by Wilcoxon matched pairs test or Mann-Whitney U test.
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During the 1-year follow-up period there were 11 AMI patients with
a recurrent cardiovascular event. Fig. 3 shows the distribution of factor
XIa levels among patients that experienced a recurrent event during
follow-up and those that did not. Therewas no signiﬁcant difference be-
tween the groups. To get more insight into the predictive value of factor
XIa plasma levels, we determined the ORs for a recurrent cardiovascular
event after dichotomizing the data to low levels (bmedian of the total
group) versus high levels (≥median of the total group). However, a
high factor FXIa level at baseline was not signiﬁcantly associated with
endpoints; unadjusted OR of 1.26 (95% CI: 0.33-4.7) for high compared
to low factor XIa levels. Adjustment for the potential confounders
hypertension and sex (baseline characteristics with P-value ≤0.1 in
chi-square) did not result in a signiﬁcant association with endpoints,
but enhanced the OR to 1.77 (95% CI: 0.42-7.49).Discussion
In this studywe report the development and ﬁrst application of a new
thrombin generationbased factor XIa assay,which enables the quantiﬁca-
tion of factor XIa levels in plasma. By using an inhibitory anti-factor XIa
antibody with a high binding afﬁnity for factor XIa, we demonstrated
that the endogenous factor XIa concentration was the only determinant
of the assay, without contribution of other activated coagulation factors,
such as small amounts of factor IXa and factor Xa. The measurement of
patients’ plasma samples measured in the presence of an inhibitory
anti-factor XIa antibody resulted in complete inhibition of thrombinTable 2
Levels of activated factor XI and other coagulation markers in AMI patients (N = 56) on admi
Admission
Factor XIa (pM) 3.7 (2.7-5.5)
TG at 1 pM TF trigger
Lag time (min) 6.0 (4.9-7.1)
ETP (%) 150 (132-176)
Peak height (%) 220 (177-281)
D-dimer (ng mL-1) (b500) 360 (260-600)
Fibrinogen (g L-1) (2-4) 3.2 (2.8-3.8)
Factor XIa-antitrypsin (A.U.) 0.26 (0.23-0.31)
Factor XIa-C1 inhibitor (A.U.) 0.22 (0.16-0.36)generation. Validation of the assay resulted in CVs b12% and b17% for
the high and low FXIa control sample, respectively.
Since the revised model of coagulation in 1991 [8], introduced after
the ﬁnding that thrombin can activate factor XI [8,9], an increasing in-
terest in factor XI and its role in thrombosis has existed. In the revised
coagulationmodel the activation of factor XI by thrombin causes a feed-
back mechanism resulting in the secondary generation of thrombin.
This sustained thrombin generation results in the formation of ﬁbrin
and helps protect ﬁbrin from rapid proteolysis by the activation of
thrombin-activatable ﬁbrinolysis inhibitor [10,11]. The procoagulant
and anti-ﬁbrinolytic effects of factor XI could imply that increased activ-
ity levels of factor XI are associatedwith an increased thrombotic risk. In
the present prospective cohort study in patients with a ﬁrst AMI we
found that during the acute event the plasma concentration of factor
XIa was signiﬁcantly higher compared to 6 months after the event. Fur-
thermore, baseline factor XIa plasma levels were signiﬁcantly increased
compared to the factor XIa plasma levels in apparently healthy control
subjects. Also, the median factor XIc concentration was signiﬁcantly
higher in AMI patients than in healthy controls. Although in both pa-
tients and controls the median factor XIc level was within the normal
reference range.
Comparable to the factor XIa plasma level, the thrombin potential
and the level of factor XIa-C1 inhibitor were enhanced at baseline,
which was also demonstrated in previous studies of this cohort of ﬁrst
AMI patients [25,29]. In contrast, the levels of the coagulation activation
markers, D-dimer andﬁbrinogen,werewithin the normal range anddid
not signiﬁcantly change after 6 months follow-up.
The relationship between factor XI activation and atherothrombotic
events has been investigated in a limited number of studies. Twossion and at 6 months follow-up.
6 months P-value
2.8 (1.9-4.3) 0.001
7.0 (5.0-7.8) 0.033
113 (90-140) b0.0001
123 (91-171) b0.0001
375 (218-713) 0.649
3.1 (2.8-3.5) 0.303
0.25 (0.23-0.30) 0.147
0.20 (0.15-0.34) 0.002
Fig. 3. Distribution of factor XIa plasma levels among AMI patientswith andwithout a
recurrent cardiovascular event during follow-up. Plasma levels of factor XIa on admis-
sion in patients who suffered from a ﬁrst acute myocardial infarction. The factor XIa levels
are subdivided into patients with a recurrent cardiovascular event (N = 11) within the
ﬁrst year after the AMI and those that did not have a recurrent event (N = 45).
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sured as a complex with C1 esterase inhibitor and α1-antitrypsin,
could be determined in patients with AMI [5,29]. Minnema and col-
leagues detected factor XIa-C1 inhibitor complexes, reﬂecting the
acute activation of factor XI, in 24% of patients with AMI, 8% of patients
with unstable angina pectoris and 4% of patients with stable angina
pectoris. However, this effect was not observed for factor XIa-α1-
antitrypsin, which reﬂects more chronic activation of factor XI. Further-
more, in a study performed in patients with coronary artery disease, the
factor XI activity in plasmawas assessed using a clotting assay, based on
the prolongation of the clotting timeupon addition of an inhibitory anti-
factor XIa antibody [4]. Quantiﬁable plasma levels of factor XIa were
detected in 96% of acute coronary syndrome patients and 76% of stable
angina patients with a history of previous MI. Only 21% of stable coro-
nary artery disease patients without previous MI displayed factor XI
activity and no factor XI activity could be observed in healthy volun-
teers. The same factor XIa clotting assaywas used in various subsequent
studies investigating the factor XI activity in patients with different car-
diovascular diseases, which demonstrated the presence of circulating
factor XIa in patients with cerebrovascular ischemic events [6,30], aortic
stenosis [31] and stable angina pectoris [32].
In contrast to our thrombin generation based factor XIa assay, the
potential drawback of the clotting assay used in these studies is that
the antibody may give an overestimation due to an antibody induced
shift from inhibitor-complexed factor XIa towards the free enzyme
form. In our assay, factor XIa is readily detectable while the neutralizing
antibody is only applied to check for speciﬁcity of theXIa signal. A draw-
back of both assays is that they only detect the level of free factor XIa
and not the total level, since both assays cannot detect the amount of
factor XIa circulating in complex with inhibitors. In the present study
we observed increased plasma levels of factor XIa in AMI patients during
the acute thrombotic event. This maymean that more factor XIa is gen-
erated during AMI or that there is a slower rate of factor XIa inhibition,
allowing more of the factor XIa that is formed to circulate in its free
form.
The exact pathway of factor XIa generation in thrombotic patients is
still unclear. The two main physiological plasma activators of factor XI
are factor XIIa [7] and thrombin [8,9]. However, recent studies suggest
that there are different roles for the factor XIIa-mediated factor XI acti-
vation and the thrombin-mediated factor XI activation. It was demon-
strated in factor XII- and factor XI-deﬁcient mice that factor XIIa-
mediated factor XI activation was important in pathologic thrombusformation but did not contribute to haemostasis [33–36]. In contrast,
clinical studies on the relationship between factor XIIa and coronary
risk showed contradictory results [18,37,38]. Also, the two previous
studies investigating the activation of the contact system in patients
with AMI observed only an increase in factor XIa-C1 inhibitor level
and not in factor XIIa-inhibitor complexes [5,29]. These results suggest
that the increase in factor XI activationwasmost likely caused by an in-
crease in thrombin generation instead of factor XII activation.Moreover,
in their study on factor XIa activity in patients with coronary artery
disease, Butenas et al. showed evidence of factor XIa formation by
thrombin via the TF pathway [4].
Both experimental and clinical studies have demonstrated the in-
volvement of factor XI in thrombotic diseases. However, inconsistent
results have been demonstrated among these studies investigating the
association between high factor XI levels and the risk of MI. Factor XI
deﬁciency in humans has shown protective effects against venous
thrombosis and ischemic stroke [14,15], but not myocardial infarction
[39]. Furthermore, some studies revealed no signiﬁcant association
between high levels of factor XI and MI [40,41], while another study
did ﬁnd a positive association between high factor XI levels and AMI
in men [18]. In the present study we investigated whether high factor
XIa levels in patients diagnosed with a ﬁrst AMI were associated with
the risk for a recurrent cardiovascular event. Our results showed no sig-
niﬁcant association between a high factor FXIa level at baseline and the
risk for a recurrent event (OR 1.26, 95% CI 0.33-4.7), but one obvious
explanation could be a lack of power in this small study.
There were some limitations to the present study. First, we were only
able to measure factor XIa levels in 56 complete sets of plasma samples
from the two main time points (baseline and 6 months follow-up).
Second, the presence of four different inhibitors of factor XIa in plasma
will inﬂuence the stability of factor XIa in citrated blood samples. In our
analyses up to about 20% of added factor XIa is inactivated at room tem-
perature during a 1-hour period. Although these results indicate that
80% of factor XIa survives over the time needed for plasma preparation
from blood, these experiments were performed with exogenous factor
XIa and cannot be extrapolated to the endogenous factor XIa stability in
patients’ plasma samples. However, based on these experiments we
assume that because of the maximum delay between blood collection
and plasma storage in the AMI study of 1 hour, a minor underestimation
of all factor XIa values is likely. Ideally and for next studies, the time to
processing should be standardized in order to minimize such ex vivo
inactivation of enzyme.Conclusion
In this prospective cohort study in patients with a ﬁrst AMI we re-
port the ﬁrst application of a new thrombin generation based factor
XIa assay, developed for the direct quantiﬁcation of factor XIa plasma
levels. We demonstrate that in AMI patients factor XIa plasma levels
are signiﬁcantly higher during the acute ischemic event compared to
6 months after the event. Furthermore, during the acute phase, factor
XIa plasma levels are signiﬁcantly higher compared to the levels in
apparently healthy control subjects. Although the factor XIa plasma
concentration is not associated with the risk of recurrence, larger stud-
ied are needed to better determine the prognostic value of factor XIa in
atherothrombotic events.Conﬂict of interest statement
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